Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shenzhen - Delayed Quote CNY

ApicHope Pharmaceutical Group Co., Ltd. (300723.SZ)

39.83
+0.65
+(1.66%)
At close: April 30 at 3:04:10 PM GMT+8
Loading Chart for 300723.SZ
  • Previous Close 39.18
  • Open 38.17
  • Bid 39.84 x --
  • Ask 39.86 x --
  • Day's Range 38.73 - 40.50
  • 52 Week Range 12.74 - 42.42
  • Volume 10,807,134
  • Avg. Volume 12,317,171
  • Market Cap (intraday) 17.991B
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) --
  • EPS (TTM) -1.29
  • Earnings Date --
  • Forward Dividend & Yield 0.21 (0.53%)
  • Ex-Dividend Date Jun 3, 2024
  • 1y Target Est 40.26

ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical drugs. Its pediatric medicines include fuganlin and yiqi jianpi oral liquid, carboxymestrine oral solution, and xiaoer kechuanling oral liquid products; and clindamycin hydrochloride palmitate dispersible tablet, acetylguitaricin dry suspension, qinxiangqingjie oral liquid, levocetirizine hydrochloride drop, epstein hydrochloride granule, clindamycin hydrochloride palmitate granule, clindamycin hydrochloride for injection, clindamycin phosphate injection, ambroxol hydrochloride drop, montelukast sodium granule, acyclovir for injection, and oseltamivir phosphate capsule products. The company's chronic disease drugs comprise hepatocyte growth stimulating hormone and pentoxifylline for injections, kangshen granules, uqingshu granules, shenbai lotion products, compound monoammonium glycyrrhizinate S and lansoprazole for injections, houttuynia sodium tablets, omeprazole sodium and bromhexine hydrochloride for injections, huixinkang tablets, amlodipine benzenesulfonate dispersible tablets, yanhunin and sodium ferulate for injections, cyclic adenosine phosphate and ambroxol hydrochloride for injections, valsartan amlodipine tablets, and nifedipine controlled release tablets, as well as tricorutin, aceglutamide, vinpocetine, and doxofylline for injections. In addition, it offers compound xiangrui water, yinhuang oral liquid, and xiongdan chuanbei oral liquid products; venlafaxine hydrochloride sustained-release capsules; and levofloxacin hydrochloride, sodium ozagrel, brain protein hydrolysate, and ganciclovir for injections. The company was formerly known as ApicHope Pharmaceutical Co., Ltd and changed its name to ApicHope Pharmaceutical Group Co., Ltd. in December 2024. ApicHope Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Guangzhou, China.

www.apichope.com

1,484

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300723.SZ

View More

Performance Overview: 300723.SZ

Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300723.SZ
133.47%
SSE Composite Index (000001.SS)
2.17%

1-Year Return

300723.SZ
76.80%
SSE Composite Index (000001.SS)
5.61%

3-Year Return

300723.SZ
119.51%
SSE Composite Index (000001.SS)
7.61%

5-Year Return

300723.SZ
169.69%
SSE Composite Index (000001.SS)
14.65%

Compare To: 300723.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300723.SZ

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    17.99B

  • Enterprise Value

    19.68B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.94

  • Price/Book (mrq)

    9.30

  • Enterprise Value/Revenue

    16.34

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -48.49%

  • Return on Assets (ttm)

    -5.34%

  • Return on Equity (ttm)

    -26.00%

  • Revenue (ttm)

    1.2B

  • Net Income Avi to Common (ttm)

    -583.96M

  • Diluted EPS (ttm)

    -1.29

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    817.08M

  • Total Debt/Equity (mrq)

    125.98%

  • Levered Free Cash Flow (ttm)

    -604.17M

Research Analysis: 300723.SZ

View More

Company Insights: 300723.SZ

Research Reports: 300723.SZ

View More

People Also Watch